[
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The cut-point for dichotomizing VAF was determined by visualizing age-adjusted log relative hazards of OS within patients who are CH-positive, using a restricted cubic spline function of VAF (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CH was present in all patients who died prior to day 100 (n = 10) (supplemental Table 4).CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "DNMT3A, TET2, and ASXL1 mutations were common (Figure 1A); the prevalence of PPM1D variants (21/97, 22%) and TP53 variants (7/97, 7%) in our study was higher than that of the general population,47 but consistent with that seen following cytotoxic chemotherapy.19 The prevalence of CH varied by age: CH was present in 45% (95% CI, 28-64) of patients aged 60 to 64 years, 64% (95% CI, 44-81) of patients aged 65 to 69 years, and 75% (95% CI, 58-88) of those 70 years and above (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CH clone size also positively correlated with patient age (Figure 1B-C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The presence of pretransplant CH was associated with a significantly shorter survival after alloBMT: 3-year OS 78% (95% CI, 65-94) without CH vs 47% (95% CI, 35-63) with CH (unadjusted hazard ratio [HR], 3.1; 95% CI, 1.4-6.8; P < .001; Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PFS was also worse in those patients with CH (Figure 2B), with a 3-year PFS of 39% (95% CI, 28-55) vs 60% (95% CI, 43-82) in CH-negative patients.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The risk of NRM was significantly higher in recipients with CH (cumulative incidence of 1-year NRM was 11% [95% CI, 1-22] vs 35% [95% CI, 23-48], unadjusted subdistribution HR [SDHR], 3.4; [95% CI, 1.4-8.5], P = .009; Figure 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "CH was not associated with the risk of relapse (Figure 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 3-year OS was 78% (65%-94%) for patients without CH, 50% (37%-68%; HR, 2.74; [95% CI, 1.22-6.16]) for those with a VAF between 1% and 10%, and 33% (15%-74%; HR, 5.08; [95% CI, 1.9-13.59]) in those with a VAF ≥10% (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The 1-year cumulative incidence of NRM was 11% (1%-22%) for those without CH, 27% (SDHR, 2.57; [95% CI, 0.98-6.76, P = .056]) in patients with VAF 1% to 10%, and 67% (HR, 7.97; [95% CI, 2.68-23.68]) with VAF ≥10% (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "An analysis of the number of distinct CH mutations on outcomes showed similar results, with worse outcomes in patients with more than 1 CH mutation with regard to OS, PFS, and NRM (Figures 3A-C), but no difference in relapse (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "CRS and GVHD\nThe incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The incidence of grade 2 to 4 acute GVHD was not significantly different between the cohorts (supplemental Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Grade 3 to 4 GVHD incidence did appear to be higher as the level of CH increased, although the relationship was not statistically significant: the 1-year cumulative incidence of grade 3 to 4 GVHD was 5% (95% CI, 0-13) in patients without CH, 10% (SDHR, 2.0 [95% CI, 0.39-10.2]; P = .4) in those with 1% to 10% VAF, and 25% (95% CI, 0-52; SDHR, 4.99; [95% CI, 0.86-28.88]; P = .07) in those with >10% VAF (supplemental Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  }
]